Please assess the completion status of the following clinical trial:

Trial Title: Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic colorectal cancer, histologically confirmed, first or second metastatic line~* K-RAS wild-type~* Adjuvant prior chemotherapy allowed provided that all toxicities are grade \< or = 1 (excepted alopecia and neuropathy)~* Age between 18 and 80 years~* WHO Performance Status \< or = 2~* Complete initial assessment before first treatment administration for imaging and pharmacogenetic, within 15 days for biology, and within 7 days for clinical examination.~* Haematologic and hepatic parameters : neutrophils \> or = 1500 /mm3, platelets \> or = 100000/mm3, Total bilirubin \< or 2 x ULN, AST and ALT \< or = 3 x ULN, APL \< or = 5 x ULN~* Absence of total dihydropyrimidine dehydrogenase deficiency~* Patient able to comply with study requirements~* Signed written informed consent~Exclusion Criteria:~* History or presence of an other cancer, excepted cutaneous cancer (basocellular carcinoma), in situ cancer of the cervix or breast cancer curatively treated~* Any other concomitant anti-cancer therapy~* Prior anti EGFR therapy, anti angiogenic therapy is allowed~* Prior cyclines hypersensitivity~* Treatment with cyclines within 7 days before randomization~* Presence of a rash at randomization time~* Symptomatic or uncontrolled ventral nervous system metastases~* Total dihydropyrimidine dehydrogenase deficiency~* No recovery of any toxicity Grade \< or = 1 related to a past anticancerous treatment excepted for alopecia and neuropathy~* Active inflammatory bowel disease or other bowel~* Significant serious pathology or any unstable medical condition (cardiac pathology uncontrolled, myocardial infarction within 6 months before enrollment, systemic active uncontrolled infection)~* atropine contra-indication~* any investigational agent without marketing authorization within 4 weeks before enrollment~* Patient who is pregnant or breast feeding~* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
- Arm B (Type: ACTIVE_COMPARATOR): Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.

Based on this trial design, predict the completion outcome and termination type (if applicable).